First Time Loading...

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 753.68 USD -0.52% Market Closed
Updated: Mar 1, 2024

Intrinsic Value

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. [ Read More ]

The intrinsic value of one LLY stock under the Base Case scenario is 335.79 USD. Compared to the current market price of 753.68 USD, Eli Lilly and Co is Overvalued by 55%.

Key Points:
LLY Intrinsic Value
Base Case
335.79 USD
Overvaluation 55%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Eli Lilly and Co

Backtest LLY Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LLY stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Robust Growth and Expansion Drive Outlook
2023-Q4 Earnings Call

Robust Growth and Expansion Drive Outlook

Despite Trulicity's intermittent order delays and limited availability impacting its volume, the company's growth story is largely positive, propelled by Mounjaro's stellar rise in revenue—from $1.4 billion in Q3 to over $2.2 billion in Q4 2023, a roughly 30% increase quarter-on-quarter. Mounjaro’s U.S. access expanded to 90% across commercial and Part D plans. Zepbound, approved in November for obesity treatment, hit $176 million in Q4 sales, with about 75% from channel stocking. The company is confident in its commercial portfolio, with Mounjaro and newly launched Zepbound expected to be significant growth drivers. Overall, the company guides nearly 30% revenue growth in 2024 for its core business and will continue to invest in innovation and manufacturing to fuel future growth.

Financials

Balance Sheet Decomposition
Eli Lilly and Co

Current Assets 23B
Cash & Short-Term Investments 2.5B
Receivables 10.4B
Other Current Assets 10.1B
Non-Current Assets 34.9B
Long-Term Investments 2.7B
PP&E 11.9B
Intangibles 10.9B
Other Non-Current Assets 9.5B
Current Liabilities 22B
Accounts Payable 2.4B
Accrued Liabilities 12.8B
Other Current Liabilities 6.8B
Non-Current Liabilities 24.7B
Long-Term Debt 17.9B
Other Non-Current Liabilities 6.8B
Efficiency
Fundamental Scores

LLY Profitability Score
Profitability Due Diligence

Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE
Negative Free Cash Flow
71/100
Profitability
Score

Eli Lilly and Co's profitability score is 71/100. The higher the profitability score, the more profitable the company is.

LLY Solvency Score
Solvency Due Diligence

Eli Lilly and Co's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Short-Term Solvency
Average D/E
54/100
Solvency
Score

Eli Lilly and Co's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 778.21 USD with a low forecast of 545.4 USD and a high forecast of 997.5 USD.

Lowest
Price Target
545.4 USD
28% Downside
Average
Price Target
778.21 USD
3% Upside
Highest
Price Target
997.5 USD
32% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LLY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LLY Price
Eli Lilly and Co

1M 1M
+14%
6M 6M
+35%
1Y 1Y
+141%
3Y 3Y
+276%
5Y 5Y
+528%
10Y 10Y
+1 465%
Annual Price Range
753.68
52w Low
309.82
52w High
782.06
Price Metrics
Average Annual Return 33.72%
Standard Deviation of Annual Returns 25.75%
Max Drawdown -18%
Shares Statistics
Market Capitalization 713.5B USD
Shares Outstanding 950 163 968
Percentage of Shares Shorted 0.56%

LLY Return Decomposition
Main factors of price return

What is price return decomposition?

LLY News

Other Videos

Last Important Events
Eli Lilly and Co

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Eli Lilly and Co

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Eli Lilly and Co Logo
Eli Lilly and Co

Country

United States of America

Industry

Pharmaceuticals

Market Cap

713.5B USD

Dividend Yield

0.69%

Description

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 35,000 full-time employees. The firm is engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products across the world. The firm's diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta and Trulicity. Its oncology products include Alimta, Cyramza, Erbitux, Retevmo, Tyvyt and Verzenio. The firm's immunology products consist of Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, Reyvow and Zyprexa. Its other therapies consist of Bamlanivimab, etesevimab, Cialis and Forteo. The firm manufactures and distributes its products through facilities in the United States, including Puerto Rico, and about eight other countries. Its products are sold in approximately 120 countries. Its subsidiaries include Acanthas Pharma, Inc., Alnara Pharmaceuticals, Inc., ARMO Biosciences, Inc., and Avid Radiopharmaceuticals, Inc., among others.

Contact

INDIANA
Indianapolis
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
+13172762000.0
https://www.lilly.com/

IPO

1970-07-09

Employees

35 000

Officers

Chairman, CEO & President
Mr. David A. Ricks
Executive VP & CFO
Ms. Anat Ashkenazi
EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Dr. Daniel M. Skovronsky M.D., Ph.D.
Executive VP, General Counsel & Secretary
Ms. Anat Hakim J.D.
EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA
Mr. Patrik Jonsson
Chief Accounting Officer & VP of Finance
Mr. Donald A. Zakrowski
Show More
EVP & Chief Information and Digital Officer
Mr. Diogo Rau
EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Alonzo Weems
Executive Vice President of Human Resources & Diversity
Mr. Eric Dozier
Senior VP & President of Elanco Animal Health
Mr. Jeffrey N. Simmons
Show Less

See Also

Discover More
What is the Intrinsic Value of one LLY stock?

The intrinsic value of one LLY stock under the Base Case scenario is 335.79 USD.

Is LLY stock undervalued or overvalued?

Compared to the current market price of 753.68 USD, Eli Lilly and Co is Overvalued by 55%.